Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fuzuloparib - Jiangsu HengRui Medicine

Next Previous
Drug Profile

Fuzuloparib - Jiangsu HengRui Medicine

Alternative Names: Fluzoparib; HS-10160; SHR 3162

Latest Information Update: 04 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Chinese PLA General Hospital; Jiangsu Hengrui Medicine Co.; Tianjin Medical University Cancer Institute and Hospital
  • Class 2 ring heterocyclic compounds; Antineoplastics; Fluorobenzenes; Phthalazines; Pyrazines; Small molecules; Triazoles
  • Mechanism of Action Poly(ADP-ribose) polymerase 2 inhibitors; Poly(ADP-ribose) polymerase-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Marketed Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase III HER2 negative breast cancer; Pancreatic cancer; Prostate cancer
  • Phase II Glioblastoma
  • Phase I/II Small cell lung cancer
  • No development reported Gastric cancer; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 24 Jun 2025 Jiangsu HengRui Medicine terminates a phase-II clinical trials in Prostate cancer (Metastatic disease, Combination therapy, Hormone refractory, Second-line therapy or greater) in China (PO) due to the sponsor R&D strategy adjustment (NCT04102124)
  • 19 Jun 2025 Jiangsu HengRui Medicine completes a phase III trial in Ovarian cancer, Peritoneal cancer and Fallopian tube cancer (Recurrent, Second-line therapy or greater) in China (PO) (NCT03863860)
  • 01 Nov 2024 Jiangsu HengRui Medicine completes a phase II clinical trial in Ovarian cancer (Combination therapy) in China (PO) (NCT04517357)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top